Medicare GLP-1 Bridge Program Launched Today (July 1, 2026): What Actually Happens Now, First-Week Playbook, and What to Do If You're in the Gap

Today, July 1, 2026, the Medicare GLP-1 Bridge Program officially started dispensing at $50/month copay for Wegovy, Zepbound, and Foundayo. CMS estimates 3.4 million Medicare Part D enrollees qualify under the tiered eligibility criteria. If you're a Medicare Part D enrollee who meets one of the three tiers (BMI ≥35; or BMI ≥30 with heart failure, uncontrolled hypertension, or CKD; or BMI ≥27 with prediabetes, prior MI, prior stroke, or PAD), this is the cheapest legitimate path to brand-name GLP-1 therapy available anywhere in the US. If you're in the gap — Medicare but not qualifying under any tier — the cheapest fallbacks are compounded semaglutide at $99/mo via Embody, $146/mo via Yucca Health, or $199/mo via TrimRx (Editor's Choice). Here's exactly what to do this week: confirm your Part D plan is participating, get your prescriber to submit the Bridge prior-auth, expect 5-14 day approval turnaround, and understand the three most common day-1 confusion points before you start calling.

The Bridge Program in one paragraph

Passed via CMS negotiated pricing authority under the Inflation Reduction Act, the Medicare GLP-1 Bridge Program covers brand-name Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo (orforglipron) at a $50/month copay for Medicare Part D enrollees who meet at least one of the three medical necessity tiers. CMS estimates $1,200-$1,300/month in negotiated manufacturer costs are absorbed by Medicare; enrollees pay $50. Dispensing began today at participating retail and mail-order pharmacies nationwide.

Full enrollment guide with the tier-by-tier criteria and PA process: Medicare GLP-1 Bridge Program: Do You Qualify.

What actually starts today

• Dispensing: participating pharmacies (CVS, Walgreens, Kroger, most independents) can fill Bridge-eligible prescriptions starting today with the $50 copay applied.
• Enrollment window: open enrollment is continuous — no annual window for Bridge specifically. Sign up as soon as your prescriber submits the Bridge PA.
• First-fill volume: CMS projected 800,000 to 1.2 million patients would attempt to fill in July. Real-world numbers will emerge in Q3 CMS transparency reports.
• Supply chain: Novo Nordisk (Wegovy), Eli Lilly (Zepbound), and Eli Lilly (Foundayo) each committed to prioritized Bridge production runs. Expect occasional first-week supply delays at high-volume pharmacies.

Your day-1 checklist

Step 1 — Confirm Bridge eligibility with your prescriber. You need one of the three tier qualifications documented on the chart: - Tier 1: BMI ≥35 (obesity class II or III) - Tier 2: BMI ≥30 + heart failure, uncontrolled hypertension, or chronic kidney disease - Tier 3: BMI ≥27 + prediabetes, prior myocardial infarction, prior stroke, or peripheral artery disease

Ask your prescriber to confirm which tier applies to you and to document the qualifying condition explicitly.

Step 2 — Confirm your Part D plan is participating. Call the number on your Part D plan card or check your plan's formulary online. Most major Part D plans (WellCare, Humana, Aetna, UnitedHealthcare, SilverScript) are participating; smaller regional plans may take a few weeks.

Step 3 — Have your prescriber submit the Bridge PA. This is a specific PA type that flags the prescription for $50 copay routing. Ask your prescriber's office to confirm they're using the Bridge PA form (not standard formulary PA). Turnaround: 5-14 days for clean submissions.

Step 4 — Choose Wegovy, Zepbound, or Foundayo. All three are $50/mo under the Bridge. Practical differences:

If you tolerated Ozempic-class drugs well, Wegovy is the natural continuation. For maximum weight loss, Zepbound has the strongest efficacy data. For patients who can't tolerate injections, Foundayo is the pill option with no fasting requirement (unlike Rybelsus).

Step 5 — Fill at a participating pharmacy. CVS, Walgreens, Kroger, Publix, and most major mail-order Part D pharmacies are set up for Bridge on day one. Independent pharmacies vary — call ahead. Expect the $50 copay to appear correctly on the first fill; if it doesn't, ask the pharmacist to re-run the claim under the Bridge PA (some pharmacy systems needed manual updates over the weekend).

Three day-1 confusion points

1. Bridge doesn't cover Ozempic or Mounjaro (only obesity-indicated GLP-1s)

Bridge covers three drugs: Wegovy, Zepbound, and Foundayo. It does NOT cover Ozempic (T2D indication) or Mounjaro (T2D indication) — even though those contain the same active molecules as Wegovy and Zepbound.

If you were on Ozempic for T2D under Part D formulary: you can stay on Ozempic through your regular Part D coverage (probably $25-$100/mo depending on your plan). No need to switch.

If you were on Ozempic off-label for weight loss: talk to your prescriber about switching to Wegovy. Same molecule, obesity-approved, now $50/mo under Bridge. See Ozempic vs Wegovy.

If you were on Mounjaro off-label: switch to Zepbound. Same molecule, weight-loss-approved, $50/mo under Bridge. See Zepbound vs Ozempic and Mounjaro for Weight Loss.

2. Compounded medications are NOT covered

Bridge covers FDA-approved brand-name medications only. Compounded semaglutide and compounded tirzepatide are explicitly excluded — regardless of pharmacy quality or physician credentialing.

If you're on compounded and qualify for Bridge: the switch is worth it — brand at $50/mo beats compounded at $99-$249/mo in nearly every case. Talk to your prescriber about transitioning to Wegovy or Zepbound. Same molecule as your compounded version. See our Ozempic to compounded switching guide for the reverse-direction protocol.

If you're on compounded and DON'T qualify for Bridge: stay on compounded. $99-$249/mo remains cheaper than brand cash retail. See Cheapest Compounded Semaglutide and Cheapest Compounded Tirzepatide.

3. Not every Part D plan is participating on day 1

CMS confirmed all major Part D carriers are participating: UnitedHealthcare, Humana, Aetna, WellCare, SilverScript, Cigna. Regional and smaller plans may take 1-3 weeks to have their pharmacy claims systems fully configured.

If your plan says "we don't have Bridge yet": ask when they expect to activate. Most laggards will be up within 30 days. In the meantime, you can pay the standard formulary rate if any (usually $100-$200/mo for Wegovy or Zepbound under Part D), then request a retroactive Bridge copay refund once your plan activates.

What to do if you're in the eligibility gap

The Bridge tiers exclude a meaningful group: Medicare Part D enrollees with BMI 27-29 who don't have any of the qualifying comorbidities. If that's you:

Cash-pay compounded is the cleanest path. Same active molecule as brand Wegovy/Zepbound, no ICD-10 required, US 503A pharmacy sourced. Ranked commission-first:

• Embody — Semaglutide $99/mo, tirzepatide $149/mo. Cheapest floor.
• Yucca Health — Semaglutide $146/mo, tirzepatide $258/mo (6-month plan). LegitScript-verified.
• TrimRx — Editor's Choice — Semaglutide $199/mo flat, tirzepatide $299/mo flat. US-licensed prescribers, monthly check-ins, lab monitoring.
• MyStart Health — Semaglutide $224/mo with code SELFLOVE25. Brand pathway built-in if your eligibility changes.
• MEDVi — Semaglutide $179 first month, $299 refills.
• SkinnyRx — Semaglutide $199/mo. Multi-format delivery.

Brand cash-pay alternatives if you specifically want FDA-approved: - NovoCare Wegovy direct: $249/mo - LillyDirect Zepbound vials: $349-$499/mo - Foundayo LillyDirect: $149/mo

Work with your prescriber on tier documentation. If your BMI is 28-29 and you have prediabetes but haven't been coded for it, ask for an A1C draw. If you have a history of controlled hypertension, ask whether "uncontrolled" is documented (needed for Tier 2 at BMI ≥30). Small documentation changes can move you into a qualifying tier.

Regulatory caveat: FDA 503B ruling still pending

The FDA's May 2026 proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List had its comment period close 2 days ago (June 29, 2026). The final rule is expected in late 2026. 503A patient-specific compounding (which is what the tracked telehealth providers use) is unaffected by this proposal and continues regardless of outcome. Full analysis: FDA 503B Compounded Ban Explainer.

FAQ

Do I need to switch pharmacies to get the Bridge copay? No — any participating pharmacy honors the $50 Bridge copay once your prescriber submits the correct Bridge PA. Confirm the pharmacy is set up on the Bridge program first (most major chains are; smaller independents may be catching up).

Can I use my current Wegovy or Zepbound prescription? Your prescriber needs to submit a Bridge PA specifically — not a standard Part D formulary PA. The existing prescription itself is fine; the PA is what unlocks the $50 copay routing.

How long does the Bridge PA take? Clean submissions: 5-14 days. If additional documentation is requested: 14-30 days. Denied first submissions can be appealed via peer-to-peer review or formal appeal (same process as standard Wegovy/Zepbound PAs). See our Wegovy PA Playbook — the process is nearly identical for Bridge.

What if my Bridge PA is denied? Most first-submission denials cite missing documentation of the qualifying tier. Get your prescriber to add: measured in-office BMI (within 30 days), qualifying comorbidity ICD-10 code(s), and comorbidity supporting labs or notes. Resubmit. Roughly 70% of appealed PAs succeed end-to-end.

Can I switch drugs after enrolling in Bridge? Yes. Switching between Wegovy, Zepbound, and Foundayo under Bridge is straightforward — your prescriber writes the new script, and the Bridge PA transfers. No re-enrollment needed for switches between the three Bridge-covered drugs.

Does Bridge cover Rybelsus (oral semaglutide)? No. Rybelsus is under Medicare Part D standard formulary (typically $25-$100/mo depending on your plan), but it's not part of the Bridge Program.

What if I lose eligibility mid-year (e.g., weight drops below BMI threshold)? Bridge coverage is re-authorized annually. If your weight drops below the qualifying tier at annual reauth, you may need to demonstrate continued medical necessity for maintenance therapy. Talk to your prescriber about maintenance-phase documentation before it becomes a problem.

Is Bridge available for veterans on VA prescription coverage? No — Bridge is specifically Medicare Part D. Veterans on VA coverage should use VA formulary rules, which have their own separate GLP-1 coverage criteria.

What about Medicare Advantage plans? If your Medicare Advantage plan includes Part D coverage (most do), Bridge applies to the Part D portion. Confirm with your Advantage plan.

For our full provider grid see the cheapest GLP-1 programs page. For the underlying tier-by-tier eligibility criteria, see our June 10 Medicare Bridge enrollment guide. For the deeper Wegovy PA process, see our Wegovy Prior Authorization Playbook. For patients in the gap: Cheapest Compounded Semaglutide and Cheapest Compounded Tirzepatide.